Attendance at Annual Biocontrol Industry meeting

Eden BioSolutions plc
("Eden" or the “Company")
Attendance at Annual Biocontrol Industry meeting
Eden BioSolutions plc (AIM: EDEN), a leader in sustainable biopesticide and biocontrol technology, announces that members of its commercial team, including Sean Smith, Chief Executive Officer and Alex Abrey, Chief Financial Officer, will be attending the Annual Biocontrol Industry Meeting (“ABIM”) in Basel, Switzerland from 20 to 22 October 2026.
ABIM is the leading international event for the global biocontrol industry, drawing more than 2,000 delegates from 65 countries, representing 800 companies. Eden’s attendance provides an opportunity for the Company to strengthen the commercial purpose by referring to industry developments, existing relationships and potential partnerships.
For further information regarding ABIM, please visit the event website at https://www.abim.ch/
For further information contact:
|
Eden BioSolutions plc |
||||||||
|
Sean Smith, Chief Executive Officer |
Via Walbrook PR |
|||||||
|
Alex Abrey, Chief Financial Officer |
|
|||||||
|
|
|
|||||||
|
Cavendish Capital Markets Limited (Nominated advisor and joint broker) |
Tel: 020 7220 0500 |
|||||||
|
Giles Balleny / Elysia Bough (Corporate Finance) |
|
|||||||
|
Harriet Ward (Corporate Broking) / Dale Bellis (Sales) |
|
|||||||
|
|
|
|||||||
|
Oberon Capital (Joint Broker) |
Tel: 020 3179 5300 |
|||||||
|
Nick Lovering / Mike Seabrook / Adam Pollock |
|
|||||||
|
|
|
|||||||
|
Walbrook PR (Media Relations & Investor Relations) |
Tel: 020 7933 8780 or eden@walbrookpr.com |
|||||||
|
Paul McManus / Nick Rome / Anna Dunphy |
Mob: +44 7980 541 893 / Mob: +44 7748 325 236 / Mob: +44 7876 741 001 |
|||||||

Notes to Editors:
Eden BioSolutions is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.
Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has three products currently on the market:
Based on plant-derived active ingredients, Mevalone® is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops. It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally.
Cedroz™ is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally. Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally.
Eden's seed treatment product (approval expected in 2026), Ecovelex was developed to safely tackle crop destruction caused by birds - a major cause of losses in maize and other crops. Ecovelex works by creating an unpleasant taste or odour that repels birds, leaving the seeds safely intact and the birds unaffected and free to find alternative food sources. The product is based on Eden's plant-derived chemistry, registered in the EU, US and elsewhere, and formulated using Eden's Sustaine® microencapsulation system.
Eden's Sustaine® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.
Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services.
For more information about Eden, please visit: www.edenresearch.com.
Follow Eden on LinkedIn, Twitter and YouTube.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE